Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-Selected CAR-NK Cells in Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT07598955Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK in thymoma, thymic carcinoma (TC), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-CAR30-NKEB-CAR5-NKEB-CARMSLN-NK
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT07598955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598955.